Federica Fascì-Spurio

Federica Fascì-Spurio

Auto-generated profile, based on publicly available information

Federica Fascì-Spurio

OSPEDALE DELL'ANGELO

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2025 in Current Obesity Reports
Verified
Journal Article
Open access
PDF file
DSDaniel Simancas-Racines
Daniel Simancas-Racines
Giuseppe AnnunziataGiuseppe Annunziata
Giuseppe Annunziata
LVLudovica Verde
Ludovica Verde
FFFederica Fascì-Spurio
Federica Fascì-Spurio
CRClaudia Reytor-González
Claudia Reytor-González
Luigi BarreaLuigi Barrea
Luigi Barrea
Purpose of Review This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine the effectiveness of specific nutritional strategies in preventing and treating this obesity-linked liver disease. Recent Findings Emerging evidence underscores the benefits of the Mediterranean diet, low-carbohydrate diets, and intermittent fasting in reducing liver fat, improving insulin sensitivity, and mitigating inflammation. Supplementing with vitamin E, omega-3 fatty acids, and silymarin can potentially reduce liver fibrosis and promote liver health. Summary MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, and nutraceutical supplementation. Integrating these strategies with lifestyle modifications, including regular physical activity, offers a comprehensive approach to improving metabolic and liver outcomes in patients with MASLD. Further research is needed to refine and personalize these therapeutic interventions.

20 April 2025 in Food and Agricultural Immunology
Verified
Journal Article
Open access
RSRosario Suarez
Rosario Suarez
EBEstefanía Bautista-Valarezo
Estefanía Bautista-Valarezo
AMAndri Matos
Andri Matos
PCPaula Calderón
Paula Calderón
FFFederica Fascì-Spurio
Federica Fascì-Spurio
Evelyn Frias-ToralEvelyn Frias-Toral
Evelyn Frias-Toral

19 June 2026 in Obesity Pillars
Verified
Journal Article
Open access
DSDaniel Simancas-Racines
Daniel Simancas-Racines
MCMartín Campuzano
Martín Campuzano
GRGianluca Rossetti
Gianluca Rossetti
LCLu Cobellis
Lu Cobellis
VPVincenzo Pilone
Vincenzo Pilone
LSLuigi Schiavo
Luigi Schiavo
Incretin-based pharmacotherapies, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, have transformed obesity management by producing substantial weight loss through appetite suppression, reduced energy intake, and gastrointestinal effects. These mechanisms may also modify dietary intake, gastrointestinal physiology, and weight-loss–related metabolic adaptations, raising concern about micronutrient disturbances during long-term treatment. This narrative clinical review synthesizes evidence on mechanistic pathways, clinical signals, and monitoring considerations related to micronutrient risk during incretin-based obesity pharmacotherapy. Evidence was integrated from dietary studies, observational cohorts, mechanistic investigations, clinical trials, pharmacovigilance reports, and literature on obesity-related micronutrient physiology. Micronutrient vulnerability appears to arise from the interaction between reduced food intake, lower dietary diversity, gastrointestinal intolerance, delayed gastric emptying, rapid weight loss, and baseline nutritional risk. The most relevant signals involve hematologic, fat-soluble, bone-related, trace element, and electrolyte domains, particularly iron, vitamin B12, vitamin D, calcium, magnesium, zinc, with additional context-dependent concerns involving thiamine, folate, vitamin A, other fat-soluble vitamins and potassium. Most abnormalities reported to date are subclinical or indirect, but clinically meaningful consequences may occur in susceptible individuals, including those with prior bariatric surgery, gastrointestinal disorders, poor baseline diet quality, older age, or prolonged nausea and vomiting. Micronutrient risk during incretin-based obesity pharmacotherapy is likely multifactorial and patient-specific. Individualized nutritional assessment and targeted laboratory monitoring should be considered for high-risk patients, while prospective studies are needed to define incidence, clinical relevance, and evidence-based monitoring strategies.